ÂÜÀòÂÒÂ×

Karine cumulates 20 years of experience in clinical research operations, in roles with increasing responsibilities. She brings to Inversago's drug development program proven abilities in seamless clinical trial management, building strong internal cross-functional collaboration and CAO partnership. Prior to joining the leadership team, Karine Lalonde was most recently Senior Director, Clinical Operations, where she demonstrated exceptional skills in helping Inversago deliver the phase 1 program for INV-202 and favorably position the Company to launch later stage clinical trials. Previously, she was Associate Director of Clinical Operations for Ipsen following the acquisition of Clementia Pharmaceuticals Inc, where she contributed to bringing Palovarotene to NDA. Along her career, Karine acquired extensive experience in broad therapeutic areas ranging from Diabetes to Oncology and Musculoskeletal Pare diseases, including pediatric trials. Her strive to learn and understand all aspects of clinical operations allowed her to gain strong skills and in-depth knowledge from end-to-end study conduct process. She also participated in multiple site inspections and audits. Karine holds a MSc in Clinical Pharmacology from Université de Montréal.